Introduction
Dengue viruses are positive-sense, single-stranded RNA viruses belonging to the genus Flavivirus, family Flaviviridae (Chambers et al., 1990) . The four antigenically distinct serotypes of dengue virus (dengue-1, -2, -3 and -4) cause an estimated 100 million infections, resulting in widespread dengue fever (DF) and at least 250 000 cases of dengue haemorrhagic fever (DHF), each year (Halstead, 1988) . These viruses are transmitted primarily by the mosquito Aedes aegypti and are endemic throughout the tropical and sub-tropical regions of the world. In recent years, a major expansion of dengue transmission has occurred throughout the tropical Americas, accompanied by an alarming increase in the number of DHF cases. Despite the public health importance of DF and DHF, effective control measures are not available other than vector reduction, which has proven difficult and costly to sustain over time (Gubler & Trent, 1993) . Although vaccines Author for correspondence : Kanakatte Raviprakash.
Fax j1 301 319 7451. e-mail ravik!nmripo.nmri.nnmc.navy.mil are available to two related flaviviruses, yellow fever (YF) virus and Japanese encephalitis (JE) virus (Barrett, 1997 a, b) , decades of effort have not produced a successful dengue virus vaccine. Live-attenuated dengue viruses, while immunogenic (Bhamarapravati & Yoksan, 1989) , have been associated with unacceptable reactogenicity and clinical complications (Edelman et al., 1994 ; McKee et al., 1987) . Inactivated dengue viruses have been reported to be less immunogenic (Schlesinger, 1977) and recombinant dengue proteins have failed to protect non-human primates from homologous dengue virus challenge (Deubel et al., 1988 ; Eckels et al., 1994) .
We have been exploring DNA vaccine technology, in which plasmids expressing appropriate viral antigens are used for immunization. This approach has been shown by others to induce an immune response in animal models against a number of different viruses, including several flaviviruses. DNA vaccine constructs for Murray Valley encephalitis virus (Colombage et al., 1998) , JE virus (Konishi et al., 1998) , Russian spring-summer encephalitis virus (Schmaljohn et al., 1997) , Central European encephalitis virus (Schmaljohn et al., 1997) , and St Louis encephalitis virus (Phillpotts et al., 1996) have all been reported Vaccine DNA. The vaccine construct D1ME contained the dengue-1 pre-membrane (prM) and full-length envelope (E) genes cloned into vector pVR1012 (Vical Inc.) . The dengue-1 sequence (strain Western Pacific 74) from nucleotide 369 to 2392 (Mason et al., 1987) was amplified by RT-PCR by using the primers 5h ACGTCTCGAGAGGACCATGGGGATCATTTTTATTTTGCTGAT 3h and 5h AGTGGATCCTCATTACGCCTGAACCATGACTCCTAG 3h. The PCR product was digested with restriction endonucleases XhoI and BamHI and cloned into pVR1012 that was cut with SalI and BamHI. The vaccine construct was purified by alkaline lysis followed by two isopycnic centrifugations through CsCl gradients and by extensive dialysis with PBS (Maniatis et al., 1984) . The purified DNA was tested for expression of dengue-1 E by indirect immunofluorescence of transfected 293 cells (ATCC) with dengue-1 hyperimmune mouse ascitic fluid. pVR1012 vector plasmid DNA and pUC19 DNA were purified by similar procedures. pUC19 DNA was used as a source of immunostimulatory sequences (ISS) (Porter et al., 1998) .
Immunizations. Monkeys were immunized intramuscularly (i.m.) or intradermally (i.d.) as shown in Table 1 . For i.m. vaccinations, 0n5 ml vaccine DNA in PBS was divided into two inoculations of 0n25 ml in each tibialis anterior muscle. For i.d. inoculations, 0n5 ml total volume of vaccine DNA was distributed among six sites in the anterior thoracic area. The vaccinations were repeated at months 1 and 5 after the initial inoculation. The i.d.-vaccinated monkeys (groups 4 and 5) received a fourth inoculation at month 12.
Antibody analyses. The monkeys were bled at monthly intervals and their sera were tested for dengue-1-specific antibody by ELISA and\or PRNT. IgG antibody was detected by ELISA as described previously (Ansari et al., 1993) except that PEG-precipitated dengue-1 virions were used as the antigen and a peroxidase-labelled anti-human Ig was used as the conjugate. Antibody avidity measurements were performed by comparing antibody binding to antigen in the presence and absence of 6 M urea in a standard ELISA (Narita et al., 1998) . Briefly, sera were diluted so as to obtain a standard ELISA absorbance of between 0n8 and 1n5. ELISA was performed in duplicate microtitre plates. After antibody binding, both plates were washed three times with wash buffer. To one plate, 200 µl wash buffer was added per well, and 200 µl wash buffer per well containing 6 M urea was added to the other plate. Both Table 1 . Study design of dengue-1 DNA vaccine trial in rhesus macaques
Group
Route n D1ME* (1 mg)
None ‡ 2 k k k * Vaccine candidate 1012D1ME (dengue-1 prM and E genes cloned into vector pVR1012). † One of two animals died at month 3 due to unrelated causes. ‡ Dengue-naive animals. plates were incubated for 5 min at room temperature. The buffers were removed and the plates were washed three more times with wash buffer. Incubations with conjugate and substrate were carried out according to BGGA DNA vaccine for dengue virus DNA vaccine for dengue virus the standard ELISA protocol. The avidity index (AI) was calculated as 100i (A [+urea] \A [−urea] ). An antibody-capture ELISA was used for IgM antibody detection as described previously (Simmons et al., 1998) . PRNT was performed with LLCMK # cells as described previously (Russell et al., 1967) using twofold serial dilutions of serum samples. A pool of the sera of animals collected before they were primed was used as the negative control for PRNT. Fifty % PRNT titres (PRNT &! ) were determined by probit analysis. PRNT &! titres were considered to be zero if a 1 : 10 serum dilution caused less than 50 % reduction.
In vitro stimulation of T cells. Peripheral blood lymphocytes (PBL) were purified by Ficoll-Hypaque centrifugation from heparinized blood collected at months 8 and 11 after the initial inoculation. Cells (3i10') were plated into each well of a 24-well plate and cultured for 4 days in a total volume of 1 ml in the presence of concanavalin A (10 mg\ml), dengue-1 virus (5i10% p.f.u.) or inactivated dengue-1 virus (5i10% p.f.u. equivalent). Supernatant fluids were assayed for secreted γ-interferon (IFN-γ) by ELISA. Briefly, flat-bottomed microtitre plates (Maxisorp, NUNC) were coated with 100 µl per well monoclonal antibody BMS-107 (anti-human IFN-γ, Alexis Corp.) at 2 µg\ml. The plates were washed once with PBS\0n05 % Tween 20 (wash buffer) and blocked for 1 h at 37 mC with wash buffer containing 0n5 % BSA. Plates were washed five times with wash buffer and 50 µl test samples or IFN-γ standard solution (Endogen) was added to wells and incubated for 2 h at 37 mC. Plates were washed as before and 100 µl of biotinylated monoclonal antibody 7B6-1 (anti-human IFN-γ, Diapharma) was added to each well and incubated for 1 h at 37 mC. Plates were washed as before and developed by using streptavidin-alkaline phosphatase (100 µl, 1 h, 37 mC) and substrate p-nitrophenyl phosphate. The difference in absorbance at 405 and 620 nm was used as the end point. Plates were read every 30 min until the A %!& minus A '#! for the 1000 pg\ml standard registered a reading between 1n5 and 2n0. The concentration of IFN-γ in the test samples was determined from the standard curve.
For inactivation of dengue-1 virus, 9 ml virus stock (10& p.f.u.\ml) was mixed with 1 ml 1 M Tris-HCl (pH 9n0) and 1n1 ml 1% β-propiolactone. The mixture was incubated at 37 mC for 1 h with intermittent swirling. The inactivated virus was pelleted by centrifugation at 32 000 r.p.m. for 2 h in a Beckman SW41 rotor. The pellet was washed once with RPMI-1640 medium containing 10 % foetal bovine serum and resuspended in 0n9 ml of the same medium. To confirm inactivation, a 0n1 ml aliquot of this preparation was tested in a plaque assay with Vero cells.
Virus challenge and viraemia. Two separate virus challenge experiments were conducted. Groups 1, 2, 3 and 6 (Table 1) were challenged at 9 months after the initial immunization. The three monkeys from groups 3 and 6 served as the control group for this challenge experiment. Groups 4, 5 and 7 were challenged at 15 months. The naive monkeys in group 7 served as controls for this experiment. Each monkey was bled prior to challenge and then inoculated subcutaneously in the upper left arm with 0n5 ml of a solution containing 1n25i10% p.f.u. of dengue-1 virus. The virus used for challenge (dengue-1 Western Pacific 74) was prepared from infected foetal rhesus lung cells and was kindly provided by K. Eckels (Walter Reed Army Institute of Research). Monkeys were bled daily for 10 days and again on days 14 and 29 after challenge and the sera were used to measure viraemia and antibody responses. Viraemia was measured by inoculating 25 cm# flasks of confluent Vero cells in duplicate with 0n2 ml of a 1 : 3-diluted serum sample. The inoculated cells were incubated for 10 days at 37 mC in a CO # incubator. The cells were then scraped off the flasks, washed with PBS and spotted in duplicate onto immunofluorescence slides. The slides were processed for indirect immunofluorescent staining by using dengue-1 hyperimmune mouse ascitic fluid and FITC-conjugated anti-mouse Ig and examined under a fluorescence microscope with appropriate positive and negative controls.
Results

Dengue-1 DNA vaccine is immunogenic in rhesus monkeys
A dengue virus-specific antibody response was seen as early as 1 month after priming in monkeys that were vaccinated i.m. (Fig. 1 a) . There was a trend towards an increase in the antibody response following boosts at months 1 and 5. No significant difference was observed in the antibody levels of monkeys that were co-immunized with pUC19 plasmid versus those immunized with vaccine alone. Compared with the i.m.-vaccinated monkeys, the antibody levels of i.d.-vaccinated monkeys were lower and declined more rapidly over time (Fig. 1 b) .
The ability of sera of immunized monkeys to neutralize dengue-1 virus was tested by PRNT (Table 2) . One month after the second boost (month 6), sera from six of eight i.m.-vaccinated monkeys showed PRNT &! titres ranging from about 1 : 20 to 1 : 360. The PRNT &! titres, however, declined over time. As with ELISA, co-immunization with pUC19 DNA did not increase the neutralizing antibody levels significantly. Two of the i.m.-vaccinated monkeys (MV4 and MV8) failed to 
Monkeys vaccinated i.m. are protected from live dengue-1 virus challenge
The eight i.m.-vaccinated monkeys (MV1-MV8) and three control vaccinated monkeys (MC1, DC1 and DC2) were challenged at month 9 by subcutaneous inoculation with 1n25i10% p.f.u. dengue-1 virus. These monkeys were bled daily for 10 days and the sera were analysed for the presence of infectious virus. Four of the eight i.m.-vaccinated monkeys were protected completely from developing viraemia (Table 3 , Expt 1). The other four i.m.-vaccinated monkeys showed viraemia for 2 or 3 days. The i.m.-vaccinated group thus had a median period of viraemia of 1n0 day. The three control vaccinated monkeys showed a median period of viraemia of 5 days. The reduction in viraemia of vaccinated monkeys was significant (P l 0n012 ; Kruskal-Wallis test). Among the i.m.-vaccinated monkeys, there was no difference between the groups with and without pUC19.
In a second challenge experiment, the i.d.-vaccinated monkeys (DV1-DV4), along with two naive control monkeys (N1 and N2), were inoculated with dengue virus at 15 months and viraemia was evaluated as described above. No significant reduction in viraemia was observed in the i.d.-vaccinated monkeys, which had a median period of viraemia of 4 days compared to 4n5 days for the naive controls (Table 3 , Expt 2).
Immunological memory in dengue-1 DNA-vaccinated monkeys
The sera obtained from animals following challenge with dengue-1 virus were examined by ELISA for the kinetics of IgG and IgM antibody production. For i.m.-vaccinated monkeys, IgM responses were similar to controls except that, on day 29, the levels had dropped in vaccinated monkeys compared with control monkeys (Fig. 2 a) . These i.m.-vaccinated monkeys showed a rapid rise in IgG antibody from day 7 that peaked on day 14 (Fig. 2 b) . The IgG antibody in the control monkeys was only beginning to rise on day 14 and the levels were still modest on day 29. These results indicate that the i.m.-vaccinated monkeys mounted anamnestic antibody responses to virus challenge, whereas the control monkeys showed primary antibody responses. Similar results were obtained when the IgM and IgG antibodies of i.d.-vaccinated monkeys were compared to those of naive control monkeys (Fig. 2 c, d ).
Antibody avidity
In order to determine whether there was a qualitative difference between the antibodies produced in animals that were completely protected and those produced in animals that were not completely protected, antibody avidity in the presence of 6 M urea was measured by ELISA. Monkeys MV1 and MV2 (completely protected), MV7 and MV8 (truncated viraemia) and DC1 and DC2 (control) were included in this assay. The results showed that, for vaccinated monkeys, the AI remained constant for sera collected at 7 months and on the day of challenge for the two protected monkeys (MV1, MV2) or increased for the two vaccinated monkeys that developed truncated viraemia (MV7, MV8) ( Table 4) . One of the two monkeys that was not completely protected (MV8) had an AI comparable to those of protected monkeys. On virus challenge, the control monkeys produced antibody that matured from a very low AI (1 month) to a higher AI (3 months).
T cell stimulation
PBL from two naive monkeys and two vaccinated monkeys were stimulated in vitro and the secretion of IFN-γ was measured by ELISA (Table 5) . PBL from naive monkeys could not be stimulated by dengue virus. In the two vaccinated monkeys that were tested, PBL from month 11 (2 months after dengue-1 virus challenge) were stimulated, but those from month 8 (3 months after the last immunization but 1 month before challenge) were not. PBL from month 11 were stimulated by both live and inactivated dengue-1 virus.
Discussion
We have demonstrated that a dengue virus type 1 DNA vaccine elicited neutralizing antibody responses in rhesus macaques. Upon challenge with live dengue-1 virus, half of the i.m.-vaccinated macaques were protected completely from viraemia. The remainder exhibited reduced viraemia compared with the control macaques.
We have shown previously that plasmid DNAs expressing dengue virus type 2 prM and truncated E proteins are immunogenic in mice (Kochel et al., 1997 ; Porter et al., 1998) . We have tested a series of dengue-1 DNA vaccine candidates expressing truncated or full-length E with or without prM and found that the construct expressing dengue-1 prM and fulllength E produced long-lived neutralizing antibodies in mice . Mice are not the desirable challenge model for dengue infection, however. The mouse model involves intracranial inoculation of dengue virus, which causes encephalitis, and mice are less susceptible to infection as they become older ( 6 weeks of age). Historically, rhesus macaques have been used for evaluation of dengue vaccines. These non-human primates become viraemic after subcutaneous inoculation of live dengue virus. The data presented here demonstrate that the dengue-1 DNA vaccine expressing prM and E can induce protective immune responses in the rhesus macaque model.
In recent years, the relatively new technology of DNA vaccination for several other pathogens has been tested for immunogenicity and\or efficacy in non-human primates. Wang et al. (1993) first demonstrated seroconversion of cynomolgus macaques upon i.m. inoculation with a plasmid DNA construct expressing the human immunodeficiency virus type 1 (HIV-1) envelope gene. Since then, several different HIV\simian immunodeficiency virus DNA vaccines have been shown to be immunogenic in rhesus macaques (Lekutis et al., 1997 ; Yasutomi et al., 1996) and chimpanzees (Bagarazzi et al., 1998 ; BGGD * Control animals (C1 and C2) are dengue-naive monkeys used as controls for this assay. These monkeys were not part of the vaccine study. Boyer et al., 1997) . It was further demonstrated that chimpanzees vaccinated with an HIV-1 DNA vaccine were protected from a high-dose heterologous HIV-1 challenge (Boyer et al., 1997) . Similarly, inoculation of cynomolgus macaques with a DNA vaccine for rabies virus elicited protective immune responses comparable to those elicited by the human diploid cell vaccine (Lodmell et al., 1998) . Immunogenicity of influenza virus (Donnelly et al., 1995) and hepatitis B virus (Davis et al., 1996 ; Gramzinski et al., 1998) DNA vaccines in non-human primates have also been reported. Various routes and doses of DNA vaccines have been used in primate models. Eight µg of a rabies DNA vaccine was effective in cynomolgus monkeys when delivered by gene gun (Lodmell et al., 1998) . When delivered i.d. by needle injection, the same dose failed to elicit an immune response ; the monkeys seroconverted only after an additional i.m. boost of 250 µg DNA. A Plasmodium DNA vaccine expressing the CSP gene showed a clear dose response when Aotus monkeys were immunized i.d. with 2, 0n5 and 0n125 mg doses of DNA (Gramzinski et al., 1997) . Immunizations i.m. with similar doses were ineffective. We have delivered 1 mg doses of dengue-1 vaccine DNA by needle injection via the i.m. or the i.d. route. The antibody response was better in i.m.-vaccinated monkeys compared with those that were vaccinated i.d. This could be partly due to the anatomy of the skin of rhesus macaques and the difficulty of achieving ' true ' i.d. inoculations. In contrast, BGGE DNA vaccine for dengue virus DNA vaccine for dengue virus we have observed in a separate study that the route of inoculation (i.m. or i.d.) did not affect antibody levels significantly in vaccinated Aotus monkeys .
DNA sequences containing unmethylated CpG motifs are known to stimulate humoral and cellular immune responses and have been termed ISS motifs (Krieg, 1999) . The pUC19 plasmid contains four such ISS motifs and co-immunization of pUC19 with a dengue-2 DNA vaccine candidate resulted in increased antibody responses in mice (Porter et al., 1998) . In the present study, no such stimulation was apparent in monkeys that were co-administered pUC19 DNA. It has been shown recently that the optimal ISS motifs for human cells are distinct from the mouse ISS motifs (Hartmann et al., 1999) , probably explaining the lack of effect seen in this study of pUC19 coimmunization in non-human primates, which are related more closely to humans than to mice.
It is believed that antibody can protect against dengue virus infection and that neutralizing antibody is an important component of this protection. Maternal transfer of antibody to newborns by dengue-immune mothers is known to protect infants from dengue virus infection and the duration of protection was found to correlate with the presence of neutralizing antibody (Kliks et al., 1988) . Also, mice can be protected from dengue virus challenge by the passive administration of monoclonal neutralizing antibody. Our data show a good correlation between protection and neutralizing antibody titres measured 1 month prior to challenge. The four monkeys that had measurable neutralizing antibody at month 8 are the same four that were protected completely from viraemia. At the time of challenge (month 9), although only one monkey had detectable neutralizing antibody, we presume that some biologically active neutralizing antibody below the detection threshold persisted in these animals.
While existing evidence strongly suggests that neutralizing antibody alone can be protective, other immune responses like non-neutralizing antibody or cellular immunity could also be important. For example, in studies involving dengue-2 liveattenuated vaccine (Scott et al., 1980) as well as purified inactivated dengue-2 virus vaccine (Putnak et al., 1996) in rhesus monkeys, viraemia was observed in some monkeys despite neutralizing antibody titres of 1 : 60 or greater on the day of challenge. Similarly, monkeys that had no detectable neutralizing antibody were protected from developing viraemia (Scott et al., 1980) . Mice immunized with recombinant vaccinia virus expressing dengue-4 structural proteins were protected from virus challenge although no detectable antibody could be demonstrated (Bray et al., 1989) . Passive transfer of non-neutralizing antibody directed against the non-structural protein NS-1 of dengue virus has been shown to afford partial protection in mice (Falgout et al., 1990) . Our study indicates either that very low levels of neutralizing antibody ( 10) are sufficient for protection or that other immune responses such as non-neutralizing antibody or cell-mediated immunity contribute to protection from viraemia. These observations underscore the importance of virus challenge as an end-point in dengue vaccine studies.
The antibody affinity to virus as measured by ELISA did not show marked differences between monkeys that were protected and unprotected. Two of the monkeys, MV7 and MV8, showed an increase in AI from month 7 to month 9, when the PRNT &! titres were actually declining. Because of these observations and the small number of samples in our study, no clear conclusion could be drawn about the relationships among the AI, virus neutralization and protection. However, DNA vaccination induced antibodies with AI similar to those induced by virus infection.
All the vaccinated monkeys, i.m. as well as i.d., showed anamnestic antibody responses upon virus challenge, indicating successful priming by the DNA vaccine. An anamnestic antibody response has been shown to be critical for protection of mice from encephalitis when challenged with JE virus following vaccination with a JE virus DNA vaccine (Konishi et al., 1999) . An anamnestic antibody response may be important, but not necessarily sufficient, for protection from dengue infection, since the i.d.-vaccinated monkeys were not protected despite mounting such a response. The anamnestic antibody response also suggested that there was virus replication in the vaccinated monkeys, even in the absence of detectable viraemia. It has been shown recently in the case of a tick-borne encephalitis (TBE) virus DNA vaccine that mice vaccinated and challenged with TBE virus did not develop viraemia, but did show evidence of virus replication (Kreil et al., 1998) . The strong IgM antibody response following challenge of vaccinated monkeys in our study may reflect a primary antibody response against non-structural proteins that are not expressed by the DNA vaccine.
Two representative monkeys (MV1 and MV5) were tested for T-cell memory by in vitro stimulation of PBL. Dengue-1 virus could stimulate the T cells only from PBL obtained after challenge. It has been observed that PBLs from monkeys previously infected with dengue virus are more permissive to dengue infection in vitro compared with PBLs from denguenaive monkeys (Marchette & Halstead, 1974) . Positive stimulation by inactivated dengue-1 virus indicated that the difference in stimulation of T cells observed for PBL obtained before and after dengue virus challenge is probably not due to a difference in infectability of these cells. The T-cell memory after virus challenge is probably greater because most of the known T-cell epitopes reside in the non-structural proteins (Mathew et al., 1998 ; Rothman & Ennis, 1999) , which were not part of the vaccine construct used in this study. However, the vaccine probably induces T-cell memory, as shown by the anamnestic antibody response following virus infection. Studies utilizing enriched populations of antigen-specific murine memory B cells and T-helper cells have shown that memory B cells require lower concentrations of soluble antigen and fewer T-helper cells to proliferate and differentiate compared with virgin B cells (Gray, 1993 ; Sanders et al., 1987) .
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Thus, a small number of memory T cells in our vaccinated monkeys could have gone undetected in our ELISA. It is also possible that, 3 months after the last immunization, the majority of memory T cells are in the lymphoid tissue and not in the peripheral blood.
The dengue DNA vaccine described here is the first flavivirus DNA vaccine to be tested in non-human primates. This result is a successful test of concept, demonstrating that a DNA vaccine can provide protection against dengue viraemia. It suggests that further work is required to improve and assess DNA vaccines for their ability to prevent disease due to dengue infection.
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